Evidence map›Paper›PMID 33767579›Full record

ArticleInternational journal of biological sciences2021

Basal-like breast cancer with low TGFβ and high TNFα pathway activity is rich in activated memory CD4 T cells and has a good prognosis.

Dingxie Liu, Jaydutt Vadgama, Yong Wu

Open access · goldAbstract read
In one paragraph

Article in International journal of biological sciences, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 25 papers.

0numbers the graph read from it
0cells of the map it votes in
25citing papers in PubMed
1.9field-weighted citation impact, top 12% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

25 citing papers in PubMed, 26 citations in OpenAlex.

  1. Article
  2. Article
  3. Multi-omic Profiling of Recurrence Risk Across Breast Cancer Subtypes.medRxiv : the preprint server for health sciences · 2026
    Article
  4. Article
  5. Article
  6. Review
  7. Review
  8. Article
  9. Article
  10. Review
  11. Article
  12. Article
  13. Article
  14. Article
  15. Article
  16. Telomere-Associated Gene Signatures Correlate with Prognosis, Tumor Microenvironment, and Chemosensitivity in Breast Cancer.Medical science monitor : international medical journal of experimental and clinical research · 2023
    Article
  17. Article
  18. Article
  19. Mutations inCancers · 2022
    Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors at 1 institution in 1 country.

Dingxie LiuBluewater Biotech LLC, New Providence, NJ, USA.
Jaydutt VadgamaDivision of Cancer Research and Training, Department of Internal Medicine, Charles Drew University of Medicine and Science, David Geffen UCLA School of Medicine and UCLA Jonsson Comprehensive Cancer Center, Los Angeles, CA 90095, USA.
Yong WuDivision of Cancer Research and Training, Department of Internal Medicine, Charles Drew University of Medicine and Science, David Geffen UCLA School of Medicine and UCLA Jonsson Comprehensive Cancer Center, Los Angeles, CA 90095, USA.
Charles R. Drew University of Medicine and Science · US

Funding

UCLA Clinical Translational Science InstituteUL1TR001881 · NCATS · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI ARLEEN F. BROWN, ARASH NAEIM · 2016 to 2026
$118.1M
Workshop for Junior Biostatisticians in Health ResearchU54MD007598 · NIMHD · CHARLES R. DREW UNIVERSITY OF MED & SCI · PI Ali Andalibi, Jose A Torres-Ruiz · 2012 to 2026
$60.0M
UCLA Clinical and Translational Science InstituteUL1TR000124 · NCATS · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI DUBINETT, STEVEN M. · 2012 to 2015
$57.0M
Supporting African American Churches to Promote Cancer ScreeningU54CA143931 · NCI · CHARLES R. DREW UNIVERSITY OF MED & SCI · PI VADGAMA, JAYDUTT V. · 2009 to 2022
$19.7M
Training and Mentoring ProgramsU54CA143930 · NCI · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI PIETRAS, RICHARD JOSEPH · 2009 to 2020
$7.5M
Mechanisms behind hyperglycemia-associated breast cancer risk and progressionSC1CA200517 · NCI · CHARLES R. DREW UNIVERSITY OF MED & SCI · PI WU, YONG · 2015 to 2018
$1.4M
A novel metabolic reprograming strategy for the treatment of diabetes-associated breast cancerSC1GM135050 · NIGMS · CHARLES R. DREW UNIVERSITY OF MED & SCI · PI WU, YONG · 2020 to 2023
$1.4M
Drew/UCLA Cancer Partnership ProgramU56CA101599 · NCI · CHARLES R. DREW UNIVERSITY OF MED &SCI · PI VADGAMA, JAYDUTT V. · 2003 to 2009
$1.3M
NCATS NIH HHS UL1 TR000124NCATS NIH HHS UL1 TR001881NCI NIH HHS SC1 CA200517NCI NIH HHS U54 CA143930NCI NIH HHS U54 CA143931NCI NIH HHS U56 CA101599NIGMS NIH HHS SC1 GM135050NIMHD NIH HHS U54 MD007598
6 · The paper itself

Abstract

Basal-like breast cancer (BLBC) is a type of high-grade invasive breast cancer with high risk of recurrence, metastases, and poor survival. Immune activation in BLBC is a key factor that influences both cancer progression and therapeutic response, although its molecular mechanisms are not well clarified. In this study, we examined five cancer immunity-related pathways (IFNα, IFNγ, STAT3, TGFβ and TNFα) in four large independent breast cancer cohorts (

Indexed as

Biomarkers, TumorBreast NeoplasmsCD4-Positive T-LymphocytesCohort StudiesGene Expression Regulation, NeoplasticHumansInterferon-alphaInterferon-gammaNeoplasm Recurrence, LocalPrognosisSignal TransductionSTAT3 Transcription FactorTransforming Growth Factor betaTumor Necrosis Factor-alphaBiomarkers, TumorInterferon-alphaInterferon-gammaSTAT3 protein, humanSTAT3 Transcription FactorTransforming Growth Factor betaTumor Necrosis Factor-alphaBasal-like breast cancerchemotherapyimmunity-related pathwaysprognosis

Identifiers

PMID33767579
PMCPMC7975701
OpenAlexW3129378002

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.